BLCM vs. INM, ALLR, ONCR, HSTO, CPHI, CMND, EVFM, ADTX, SCPS, and PXMD
Should you be buying Bellicum Pharmaceuticals stock or one of its competitors? The main competitors of Bellicum Pharmaceuticals include InMed Pharmaceuticals (INM), Allarity Therapeutics (ALLR), Oncorus (ONCR), Histogen (HSTO), China Pharma (CPHI), Clearmind Medicine (CMND), Evofem Biosciences (EVFM), Aditxt (ADTX), Scopus BioPharma (SCPS), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical preparations" industry.
InMed Pharmaceuticals (NASDAQ:INM) and Bellicum Pharmaceuticals (NASDAQ:BLCM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
0.5% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of Bellicum Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Bellicum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
InMed Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 11,757.71%. Given Bellicum Pharmaceuticals' higher probable upside, equities research analysts plainly believe InMed Pharmaceuticals is more favorable than Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals received 350 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 59.97% of users gave Bellicum Pharmaceuticals an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
InMed Pharmaceuticals has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Bellicum Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Bellicum Pharmaceuticals has a net margin of 0.00% compared to Bellicum Pharmaceuticals' net margin of -147.87%. Bellicum Pharmaceuticals' return on equity of -57.65% beat InMed Pharmaceuticals' return on equity.
In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.69 beat Bellicum Pharmaceuticals' score of 0.00 indicating that Bellicum Pharmaceuticals is being referred to more favorably in the news media.
InMed Pharmaceuticals has higher revenue and earnings than Bellicum Pharmaceuticals.
Summary
Bellicum Pharmaceuticals beats InMed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Bellicum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellicum Pharmaceuticals Competitors List
Related Companies and Tools
